RNAM

Avidity Biosciences, Inc. (NASDAQ:RNA) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in San Diego, California. The company went public in June 2020 and specializes in developing a novel class of precision medicines called antibody oligonucleotide conjugates (AOCs) to treat rare genetic diseases, particularly those affecting muscle function. Avidity represents a pioneering approach in biotechnology by combining the targeting capabilities of antibodies with the therapeutic potential of oligonucleotides to address previously undruggable genetic conditions.